Literature DB >> 31209816

Influence of Different Gonadotropin-releasing Hormone Agonist Administration Methods on Pregnancy Outcomes of Patients Undergoing In-vitro Fertilization-embryo Transfer.

Li Wu1, Xin-Ling Ren1, Wen Chen1, Bo Huang1, Yi-Fan Zhou1, Lei Jin2.   

Abstract

This study aimed to investigate the effect of different gonadotropin-releasing hormone agonist (GnRH-a) administration methods on pregnancy outcomes of patients undergoing in-vitro fertilization-embryo transfer (IVF-ET). Clinical data of 5217 patients who underwent IVF-ET were retrospectively analyzed. Patients were divided into the long-acting GnRH-a group (n=1330) and the short-acting GnRH-a group (n=3887) based on their various treatment plans. The clinical and laboratory embryo data and clinical pregnancy outcomes were compared between the two groups. The results showed that there were no significant differences in the age, infertility, primary/secondary infertility rate, IVF rate, body mass index (BMI), antral follicle counting (AFC), follicle-stimulating hormone (FSH) level, and the number of transplanted embryos between the two groups (P>0.05). There were no significant differences in the oocyte numbers, MII rate, fertilization rate, cleavage rate and blastocyst formation rate (P>0.05) between the two groups. The gonadotropin (Gn) using days, Gn dose and endometrial thickness were significantly greater in the long-acting GnRH-a group than those in the short-acting GnRH-a group (P<0.01). Additionally, the estradiol (E2) levels, blastocyst freezing rate, embryo utilization rate, transplant cancellation rate and abortion rate were significantly lower in the long-acting GnRH-a group than those in the short-acting GnRH-a group (P<0.01). The clinical pregnancy rate and embryo implantation rate were significantly higher in the long-acting GnRH-a group than in the short-acting GnRH-a group (P<0.01). It was concluded that use of long-acting GnRH-a can effectively reduce the transplant cancellation rate and improve the clinical pregnancy rate of the fresh cycle.

Entities:  

Keywords:  clinical pregnancy rate; gonadotropin-releasing hormone agonist; in-vitro fertilization-embryo transfer; long-acting; short-acting

Year:  2019        PMID: 31209816     DOI: 10.1007/s11596-019-2056-9

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  5 in total

1.  Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria.

Authors:  Fei Li; Tian Ye; Huijuan Kong; Jing Li; Linli Hu; HaiXia Jin; Yingchun Su; Gang Li
Journal:  Aging (Albany NY)       Date:  2020-05-29       Impact factor: 5.682

2.  Generation of cynomolgus monkey fetuses with intracytoplasmic sperm injection based on the MII-stage oocytes acquired by personalized superovulation protocol.

Authors:  Zhangqiong Huang; Yun Li; Qinfang Jiang; Yixuan Wang; Kaili Ma; Qihan Li
Journal:  J Vet Sci       Date:  2020-05       Impact factor: 1.672

3.  Effect of Excessive Body Weight and Psoriasis in Women Undergoing ICSI Procedure and State of Health of the Newborn.

Authors:  Anita Wdowiak-Filip; Artur Wdowiak; Dorota Raczkiewicz; Joanna Bartosińska; Iwona Bojar
Journal:  J Clin Med       Date:  2020-11-11       Impact factor: 4.241

4.  Machine Learning-Based Modeling of Ovarian Response and the Quantitative Evaluation of Comprehensive Impact Features.

Authors:  Liu Liu; Fujin Shen; Hua Liang; Zhe Yang; Jing Yang; Jiao Chen
Journal:  Diagnostics (Basel)       Date:  2022-02-14

5.  The follicular-phase depot GnRH agonist protocol results in a higher live birth rate without discernible differences in luteal function and child health versus the daily mid-luteal GnRH agonist protocol: a single-centre, retrospective, propensity score matched cohort study.

Authors:  Ying Zhang; Wenxian Zhao; Yifan Han; Xin Chen; Shaoyuan Xu; Yueyue Hu; Honglu Diao; Changjun Zhang
Journal:  Reprod Biol Endocrinol       Date:  2022-09-19       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.